Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Working Capital (2020 - 2021)

Historic Change in Working Capital for Gain Therapeutics (GANX) over the last 2 years, with Q4 2021 value amounting to $1.4 million.

  • Gain Therapeutics' Change in Working Capital rose 61785.79% to $1.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $329784.0, marking a year-over-year increase of 23394.26%. This contributed to the annual value of $329784.0 for FY2021, which is 23394.26% up from last year.
  • As of Q4 2021, Gain Therapeutics' Change in Working Capital stood at $1.4 million, which was up 61785.79% from -$1.7 million recorded in Q3 2021.
  • Over the past 5 years, Gain Therapeutics' Change in Working Capital peaked at $1.4 million during Q4 2021, and registered a low of -$1.7 million during Q3 2021.